This prospective observational study will evaluate the efficacy and safety of peginterferon alfa-2a in combination with ribavirin in participants with chronic hepatitis C, including participants with compensated liver cirrhosis, in clinical practice.
Study Type
OBSERVATIONAL
Enrollment
1,496
Administration of treatment will be according to local recommendation under local labeling.
Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) (less than [<] 50 International Units per Milliliter [IU/mL]) 24 Weeks Post Therapy Completion
Time frame: Baseline up to 24 Weeks Post Therapy Completion (approximately 3.5 years)
Percentage of Naive Participants With Sustained Virological Response (SVR)) and Negative HCV RNA (< 50 IU/mL) at Week 4 and 12
Time frame: Week 4, 12
Percentage of Previously Treated Participants With SVR and Negative HCV RNA (< 50 IU/mL) at Week 12
Time frame: Week 12
Percentage of Previously Treated Participants With SVR and Decrease in HCV RNA by Greater Than or Equal to (>/=) 2 Logarithm 10 From Baseline at Week 12
Time frame: Baseline, Week 12
Percentage of Naive Participants With SVR and Decrease in HCV RNA by >/= 2 Logarithm 10 From Baseline at Week 12
Time frame: Baseline, Week 12
Percentage of Previously Treated Participants With SVR, Decrease in HCV RNA by Negative HCV RNA (<50 IU/mL) at Week 24
Time frame: Week 24
Percentage of Naive Participants With SVR, Decrease in HCV RNA by Negative HCV RNA (<50 IU/mL) at Week 24
Time frame: Week 24
Percentage of Participants With SVR and Dose Reduction of Ribavirin or Peginterferon alfa-2a due to Adverse Event
Time frame: Baseline up to approximately 3.5 years
Percentage of Participants With Adverse Events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Altay Region Aids Center
Barnaul, Russia
Barnaul City Hospital #5; Therapy
Barnaul, Russia
Chelyabinsk State Medical Academy; Infectious Diseases
Chelyabinsk, Russia
Chita State Medical Academy
Chita, Russia
Irkutsk Regional Consulting and Diagnostic Clinical Center; Regional Center of Reumatolodic Deasise
Irkutsk, Russia
Kaluga regional AIDS center
Kaluga, Russia
Kazan State Medical University
Kazan', Russia
Kemerovo City Infectious Clinical Hospital; Infectious
Kemerovo, Russia
Khabarovsk-1 Road Clinical Hospital; Gastroenterology
Khabarovsk, Russia
Aids Center; Infectious
Khabarovsk, Russia
...and 47 more locations
Time frame: Baseline up to approximately 3.5 years